Leptin

Generic Name: Leptin

Drug Type: Small Molecule

CAS Number: 169494-85-3

Unique Ingredient Identifier: Q09SXY6BFI

Background: Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite signals from circulating leptin. The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized.

Indication: Investigated for use/treatment in lipodystrophy and obesity.

Clinical Trials

Clinical Evaluation of Polyherbal Coded Formulation Obesecure for Leptin Regulation and Obesity Management

Phase 2

Completed

Conditions: Leptin Deficiency
Obesity

Interventions: Drug: Leptin Human

First Posted Date: 2020-06-23

Last Posted Date: 2020-06-23

Lead Sponsor: Hafiz Muhammad Asif

Target Recruit Count: 132

Registration Number: NCT04443790

Locations: 🇵🇰
clinical trial was conducted in Karachi,Islamabad and Faisalabad, Karachi, Punjab, Pakistan

Leptin Infusion and Endothelial Vasomotor Response

Early Phase 1

Completed

Conditions: Obesity
Vasodilation
Endothelial Dysfunction
Venous Occlusion Plethysmography

Interventions: Drug: Leptin infusion in healthy men
Drug: Leptin infusion plus vasodilators in healthy men
Drug: Vasodilators in CAD patients

First Posted Date: 2020-05-05

Last Posted Date: 2023-05-09

Lead Sponsor: Stefan Soderberg

Target Recruit Count: 103

Registration Number: NCT04374500

Locations: 🇬🇧
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
🇸🇪
Umeå University Hopsital, Umeå, Sweden

The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: caffeine and ephedrine
Drug: Leptin A
Drug: caffeine, ephedrine, and leptin A

First Posted Date: 2012-10-19

Last Posted Date: 2015-12-18

Lead Sponsor: Pennington Biomedical Research Center

Target Recruit Count: 45

Registration Number: NCT01710722

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

In Vivo Leptin Signaling in Humans After Acute Leptin Administration

Phase 1

Completed

Conditions: Lean
Obese
Obese Diabetics

Interventions: Drug: leptin

First Posted Date: 2011-01-12

Last Posted Date: 2017-10-17

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 12

Registration Number: NCT01275053

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Effects of Metreleptin in Type 1 Diabetes Mellitus

Phase 1

Terminated

Conditions: Type 1 Diabetes

Interventions: Drug: Leptin

First Posted Date: 2010-12-31

Last Posted Date: 2019-08-28

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 8

Registration Number: NCT01268644

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: Fasting
Drug: Leptin administration

First Posted Date: 2010-12-10

Last Posted Date: 2010-12-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT01257841

Locations: 🇺🇸
Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States